I'm a professional

Healthcare professional

Clinical evidence, integration details, and product specifications for oncology teams.

Enter

I'm a patient or caregiver

Patient or caregiver

Information about Cureety as a daily companion during your treatment journey.

Enter
  1. Resources
  2. Our Studies
  3. TOLERATE

Observationnal • Treatment-related outcomes

TOLERATE

Treatment-related outcomes

1100

Patients enrolled in the program

34

Participating center(s) across the study

Study description

A prospective, longitudinal study to define best therapeutic class or sequence for patients with neuroendocrine tumor, in real-world settings.

Key results

Under development

Research collaboration

Discuss this study with our research team

Questions about methodology, results, or potential collaborations — our team is available to engage with researchers, clinicians and life sciences partners.

Empowering better oncology care

© 2026 Cureety — All rights reserved.

Privacy NoticeTerms of Use

Cureety Inc.

Empowering better oncology care

© 2026 Cureety — All rights reserved.

Privacy NoticeTerms of Use

Cureety Inc.